In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …

Background The glucagon-like peptide-1 receptor agonist, semaglutide, improved health
status and reduced body weight in patients with obesity-related heart failure (HF) with …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Abstract Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide
resulted in multiple beneficial effects in patients with obesity-related heart failure with …

Aims Type 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical
outcomes and treatment effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) vary …

ABSTRACT Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have
changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal …

Multiple guidelines exist for the diagnosis and management of heart failure with preserved
ejection fraction (HFpEF). We systematically reviewed current guidelines and …

The use of multiple primary endpoints in cardiovascular clinical trials could be useful
addition to the arsenal of comprehensive evaluations of meaningful clinical outcomes …